The economic burden of tuberculosis in the European Union far outweighs the cost of investing in more efficient vaccines against TB.

The story today is a far cry from the 1960s, when we led the developing countries’ fight against the disease.

Study shows isoniazid therapy should be considered for millions of HIV-infected people globally.

Re: Responsible marketing and access plans for Alere’s Determine TB-­LAM antigen test for active TB

Reported pharmaceutical association efforts to enlist opposition to the initiative are decried.

As deaths from infectious diseases rise in former Soviet countries, the EU needs to respond or face health challenges in the future, says Mario Raviglione.

Approval of and access to delamanid is crucial while further research is pending.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion for delamanid for the treatment of pulmonary multidrug-resistant tuberculosis in combination with an optimised background regimen according to WHO guidelines in patients.

FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin.

NIH-funded study suggests test may increase treatment in primary care settings.